ahlam1399
09-16-2016, 07:59 PM
UPDATE 1-EMA panel recommends **d for Pfizer?s breast cancer drug
Sept 16 (Reuters) - U.S. drugmaker Pfizer Inc's breast cancer drug, Ibrance, should be given marketing approval,an advisory committee at the European Medicines Agencyrecommended.http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=ESAT__f0QbU:29eid5hw6Wg:yI l2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?i=ESAT__f0QbU:29eid5hw6Wg:V_ sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=ESAT__f0QbU:29eid5hw6Wg:V_ sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?i=ESAT__f0QbU:29eid5hw6Wg:F7 zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=ESAT__f0QbU:29eid5hw6Wg:F7 zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/governmentfilingsNews/~4/ESAT__f0QbU
Sept 16 (Reuters) - U.S. drugmaker Pfizer Inc's breast cancer drug, Ibrance, should be given marketing approval,an advisory committee at the European Medicines Agencyrecommended.http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=ESAT__f0QbU:29eid5hw6Wg:yI l2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?i=ESAT__f0QbU:29eid5hw6Wg:V_ sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=ESAT__f0QbU:29eid5hw6Wg:V_ sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?i=ESAT__f0QbU:29eid5hw6Wg:F7 zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=ESAT__f0QbU:29eid5hw6Wg:F7 zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/governmentfilingsNews/~4/ESAT__f0QbU